Drugs, alcohol and driving
- PMID: 37067
- DOI: 10.2165/00003495-197917050-00008
Drugs, alcohol and driving
Abstract
Driving a car is a complex psychomotor and perceptual task which is subject to impairment by many factors. Several workers have studied the potential effects of drugs and alchol in crash production by epidemiological and laboratory studies. Both types of studies have yielded useful data but their limitations must be borne in mind when applying the results in pratice. Alcohol is obviously the most common single cause of traffic accidents. A progessively increased risk with increasing blood alcohol levels is well documented; fatigue and/or drugs increase this risk. Drugs are related much more infrequently to traffic accidents although on the basis of statistics, there is a potential risk with drug use. However, drugs alone are not as important as alcohol. The most significant drugs as regards driving risk are obviously certain antianxiety agents, hypnotics, stimulants, hallucinogens, marihuana, lithium and narcotic analgesics, as well as ganglionic blocking agents, insulin and sulphonylurea derivates. Patients should not drive after taking these drug until they are objectively fully alert and capable. Anticholinergics, antihistamines, antidepressants, antipsychotics, phenybutazone, indomethacin, alpha-methyldopa, and beta-blockers may in some cases cause central side effects (e.g. drowsiness) strong enough to affect driving performance. After starting therapy with these drugs, or after a significant change in dose, driving should be avoided until it is known that unwanted effects do not occur. Psychotropic drugs may enhance the deleterious effect of alcohol, and with most hypnotics there is still an effect the next morning. Some drugs (e.g. anticonvulsants or antiparkinsonian drugs) may make driving safer, but the disease (epilepsy, Parkinsonism, cardiovascular diseases, psychic disorders, etc.) ofter precludes driving. Clinicians should warn their patients about an impairment of driving skills if this is likely to occur due to the drug or the illness concerned.
Similar articles
-
Effect of drugs and alcohol on psychomotor skills related to driving.Ann Clin Res. 1974 Feb;6(1):7-18. Ann Clin Res. 1974. PMID: 4150682 No abstract available.
-
Fundamental structures in drug research.Prog Drug Res. 1976;20:385-432. doi: 10.1007/978-3-0348-7094-8_12. Prog Drug Res. 1976. PMID: 13461 Review. No abstract available.
-
The pharmacology of isolation-induced aggressive behavior in mice.Curr Dev Psychopharmacol. 1979;5:1-27. Curr Dev Psychopharmacol. 1979. PMID: 35310 Review.
-
[Mutagenic activity of psychotropic and anticonvulsant drugs].Tsitol Genet. 1976 Jul-Aug;10(4):267-76. Tsitol Genet. 1976. PMID: 10656 Review. Russian. No abstract available.
-
[Iatrogenic effects on the salivary glands].Acta Stomatol Belg. 1974;71(3):285-91. Acta Stomatol Belg. 1974. PMID: 4155239 French. No abstract available.
Cited by
-
Single and repeated dose comparison of three antihistamines and phenylpropanolamine: psychomotor performance and subjective appraisals of sleep.Br J Clin Pharmacol. 1981 Aug;12(2):179-88. doi: 10.1111/j.1365-2125.1981.tb01198.x. Br J Clin Pharmacol. 1981. PMID: 6118170 Free PMC article. Clinical Trial.
-
Effects of depot neuroleptics on driving performance in chronic schizophrenic patients.J Neurol Neurosurg Psychiatry. 1993 Aug;56(8):910-3. doi: 10.1136/jnnp.56.8.910. J Neurol Neurosurg Psychiatry. 1993. PMID: 8102393 Free PMC article.
-
Objective and subjective assessments of the effects of flupentixol and benzodiazepines on human psychomotor performance.Psychopharmacology (Berl). 1988;95(3):323-8. doi: 10.1007/BF00181941. Psychopharmacology (Berl). 1988. PMID: 2901125 Clinical Trial.
-
Low blood alcohol concentrations and driving impairment. A review of experimental studies and international legislation.Int J Legal Med. 1994;106(4):169-77. doi: 10.1007/BF01371332. Int J Legal Med. 1994. PMID: 8038109 Review.
-
Interaction of diazepam or lorazepam with alcohol. Psychomotor effects and bioassayed serum levels after single and repeated doses.Eur J Clin Pharmacol. 1985;28(5):559-65. doi: 10.1007/BF00544067. Eur J Clin Pharmacol. 1985. PMID: 3899676 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources